UDCA for NASH: End of the story?

Journal of Hepatology

Volumn 54, Issue 5, 2011, Pages 856-858

  Haedrich, Marion ^a   Dufour, Jean Franois ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Institute of Clinical Pharmacology and Visceral Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; GLUCOSE; PLACEBO; URSODEOXYCHOLIC ACID;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BILIARY CIRRHOSIS; DIABETIC PATIENT; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; EDITORIAL; ENDOPLASMIC RETICULUM STRESS; GLUCOSE HOMEOSTASIS; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

CHOLAGOGUES AND CHOLERETICS; FATTY LIVER; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URSODEOXYCHOLIC ACID;

EID: 79954792488     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.10.009     Document Type: Editorial

References (22)

1. C.K. Argo, P.G. Northup, A.M. Al-Osaimi, and S.H. Caldwell Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis J Hepatol 51 2009 371 379
2. B.A. Neuschwander-Tetri Lifestyle modification as the primary treatment of NASH Clin Liver Dis 13 2009 649 665
3. J.F. Dufour NASH and thiazolidinediones: not to be taken lightly J Hepatol 47 2007 451 453
4. J. Laurin, K.D. Lindor, J.S. Crippin, A. Gossard, G.J. Gores, and J. Ludwig Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study Hepatology 23 1996 1464 1467
5. A.E. Feldstein, A. Canbay, P. Angulo, M. Taniai, L.J. Burgart, and K.D. Lindor Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 125 2003 437 443 (Pubitemid 36929425)
6. J.D. Amaral, R.J. Viana, R.M. Ramalho, C.J. Steer, and C.M. Rodrigues Bile acids: regulation of apoptosis by ursodeoxycholic acid J Lipid Res 2009
7. M. Kugelmas, D.B. Hill, B. Vivian, L. Marsano, and C.J. McClain Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E Hepatology 38 2003 413 419 (Pubitemid 36919862)
8. M. Neuman, P. Angulo, I. Malkiewicz, R. Jorgensen, N. Shear, and E.R. Dickson Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis J Gastroenterol Hepatol 17 2002 196 202 (Pubitemid 34415674)
9. U. Ozcan, E. Yilmaz, L. Ozcan, M. Furuhashi, E. Vaillancourt, and R.O. Smith Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes Science 313 2006 1137 1140 (Pubitemid 44300242)
10. M. Kars, L. Yang, M.F. Gregor, B.S. Mohammed, T.A. Pietka, and B.N. Finck Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women Diabetes 59 2010 1899 1905
11. J.F. Dufour, C.M. Oneta, J.J. Gonvers, F. Bihl, A. Cerny, and J.M. Cereda Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis Clin Gastroenterol Hepatol 4 2006 1537 1543 (Pubitemid 44880031)
12. C. Colombo, A. Crosignani, M. Assaisso, P.M. Battezzati, M. Podda, and A. Giunta Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study Hepatology 16 1992 924 930
13. S.A. Mitchell, D.S. Bansi, N. Hunt, K. Von Bergmann, K.A. Fleming, and R.W. Chapman A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis Gastroenterology 121 2001 900 907 (Pubitemid 32959399)
14. V. Ratziu, V. DeLedinghen, F. Oberti, P. Mathurin, C. Wartelle-Bladou, and C. Renou A randomized controlled trial of high-dosei ursodeoxycholic acid for nonalcoholic steatohepatitis J Hepatol 54 2011 1011 1019
15. U.F. Leuschner, B. Lindenthal, G. Herrmann, J.C. Arnold, M. Rossle, and H.J. Cordes High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial Hepatology 52 2010 472 479
16. D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, and O.W. Cummings Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321 (Pubitemid 40770284)
17. E.M. Brunt, C.G. Janney, A.M. Di Bisceglie, B.A. Neuschwander-Tetri, and B.R. Bacon Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions [In Process Citation] Am J Gastroenterol 94 1999 2467 2474 (Pubitemid 29420675)
18. A.J. Sanyal, N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, and N.M. Bass Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 2010 1675 1685
19. Y. Zhang, and P.A. Edwards FXR signaling in metabolic disease FEBS Lett 582 2008 10 18 (Pubitemid 350297240)
20. C. Thomas, R. Pellicciari, M. Pruzanski, J. Auwerx, and K. Schoonjans Targeting bile-acid signalling for metabolic diseases Nat Rev Drug Discov 7 2008 678 693
21. K.D. Lindor, K.V. Kowdley, E.J. Heathcote, M.E. Harrison, R. Jorgensen, and P. Angulo Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 39 2004 770 778 (Pubitemid 38337657)
22. K. Promrat, D.E. Kleiner, H.M. Niemeier, E. Jackvony, M. Kearns, and J.R. Wands Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis Hepatology 51 2010 121 129